New Clinical Trials Available at Texas Retina
At Texas Retina, we remain committed to conducting ongoing research that will advance retinal care. That is why for over 20 years, for physicians have participated in more than 100 national clinical
read moreDr. Abbey First in the World to Administer Novel Trispecific Fusion Antibody EB-105 for Diabetic Macular Edema as Part of Phase Ib LOTUS Clinical Trial
On July 9, Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, dosed the first patient in the Phase Ib LOTUS trial of EB-105, the world’s first pentavalent trispecific
read moreDr. Abbey Presented Real-world Outcomes of Fluocinolone Acetonide Intravitreal Implant for Non-infectious Uveitis at ASRS 2024 Annual Meeting
Texas Retina’s Ashkan M. Abbey, MD, presented “36-month Optical Coherence Tomography Outcomes from CALM: A Registry Evaluating Treatment of Chronic Non-infectious Uveitis with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant” at the
read moreCelebrating Sally Arceneaux’s 31+ Years of Service to Texas Retina
We continue to recognize Texas Retina team members who have served our practice for 20 years or more. Today, we are honoring Sally Arceneaux, who joined Texas Retina in 1992, and currently
read moreDr. Abbey’s Research Featured in New Retina Podcast
The medical journal Retina recently released a podcast featuring research by Texas Retina Associates’ Ashkan M. Abbey, MD, on clinical outcomes and surgical technique in transconjunctival sutureless intrascleral fixation of intraocular lenses
read moreDr. Kothari and Dr. Abbey Earn “Top 10 Poster Award” at American Society of Retina Specialists 2021 Annual Scientific Meeting
A research poster by Texas Retina Associates physicians Nikisha Kothari, MD, and Ashkan M. Abbey, MD, was awarded “Top 10” honors at the American Society of Retina Specialists (ASRS) 2021 Annual Scientific
read more